US equities
|
INTC
$64.02
▼-30.47%
NVDA
$202.89
▼-5.04%
MU
$869.46
▼-6.94%
AMZN
$239.68
▼-1.69%
SNDK
$1,134.39
▼-14.71%
AMD
$497.99
▼-12.08%
AAPL
$343.90
▼-1.44%
GOOGL
$278.73
▼-1.80%
INTC
$64.02
▼-30.47%
NVDA
$202.89
▼-5.04%
MU
$869.46
▼-6.94%
AMZN
$239.68
▼-1.69%
SNDK
$1,134.39
▼-14.71%
AMD
$497.99
▼-12.08%
AAPL
$343.90
▼-1.44%
GOOGL
$278.73
▼-1.80%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Delve Bio
Delve Bio Expands Metagenomic Infectious Disease Testing with Launch of Delve Detect Plasma at IDWeek 2026
October 14, 2026
From
Delve Bio
Via
Business Wire
Delve Detect Enables Physicians to Manage Elusive Pathogens in Complex Central Nervous System Infections
June 04, 2026
From
Delve Bio
Via
Business Wire
Delve Detect Enables Neurologists to Treat CNS Infections When Conventional Testing Fails
April 16, 2026
From
Delve Bio
Via
Business Wire
Delve Bio Announces Partnership with Broad Clinical Labs for Metagenomic Next Generation Sequencing (mNGS)
October 09, 2024
From
Delve Bio
Via
Business Wire
Delve Bio presents study showing utility of metagenomic next generation sequencing (mNGS) in diagnosing neurological infections
April 17, 2024
From
Delve Bio
Via
Business Wire
Delve Bio Appoints Jim Stuart as Chief Commercial Officer
August 28, 2023
From
Delve Bio
Via
Business Wire
Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis
June 20, 2023
From
Delve Bio
Via
Business Wire